| Project/Area Number |
22KF0395
|
|---|
| Project/Area Number (Other) |
21F21037 (2021-2022)
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Multi-year Fund (2023)
Single-year Grants (2021-2022) |
|---|
| Section | 外国 |
|---|
| Review Section |
Basic Section 35030:Organic functional materials-related
|
|---|
| Research Institution | Institute of Physical and Chemical Research |
|---|
Principal Investigator |
相田 卓三 国立研究開発法人理化学研究所, 創発物性科学研究センター, グループディレクター (00167769)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
GOSWAMI ABIR 国立研究開発法人理化学研究所, 創発物性科学研究センター, 外国人特別研究員
|
|---|
| Project Period (FY) |
2023-03-08 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 2023: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2022: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2021: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | Polar Hydrophobicity / Fluorinated carriers / Hydration layer / Fast and direct delivery / Perfluorinated Crown / Supramolecular Adhesive / Water Cluster / Membrane Transporter / Supramolecular polymer / Perfluorinated monomer |
|---|
| Outline of Research at the Start |
I have successfully synthesized a series of perfluorinated crown ether derivatives that shows outstanding adhesive properties. Next, study its supramolecular polymerization behavior and find the origin of strength and toughness. Investigate the role of dynamic hydrogen bonding and F-F interaction.
|
| Outline of Annual Research Achievements |
Fast and direct permeation of drug molecules is crucial for effective biotherapeutics. Inspired by fluorous compounds disrupting the hydrogen-bonding network of water, Abir developed CyclicFP-X, a fluoro-crown ether phosphate. It efficiently delivers bioactive cargos into cancer cells without endocytic entrapment. In contrast, nonfluorinated analogues failed to internalize, while acyclic fluorous analogues showed slow uptake via endocytic trapping. CyclicFP-X, designed to be compact and highly water soluble, disrupts lipid vesicles' hydration layers. Raman spectroscopy confirmed its -OH bonds in water. CyclicFP-X, conjugated with fluorouracil (FU), NBDHEX, and doxorubicin (DOX) as an anticancer drug, demonstrated its effectiveness as a carrier for biotherapeutics.
|
